Eikon presents new PARP and WRN inhibitor data at ESMO
Eikon Therapeutics reported updated data on its PARP1 inhibitors non-brain-penetrant EIK1003 and CNS-penetrant EIK1004, alongside data on WRN helicase inhibitor EIK1005, all showing favorable safety profiles. The release reinforces the company's pipeline potential for 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed